TY - JOUR
T1 - Dopamine agonist therapy for hyperprolactinemia
AU - Bankowski, Brandon J.
AU - Zacur, Howard A.
PY - 2003/6/1
Y1 - 2003/6/1
N2 - Hyperprolactinemia significantly impairs the normal functioning of the reproductive system in women by its detrimental effects on gonadotropin secretion, ovarian follicular development, oocyte release, and corpus luteum function. Fortunately, hyperprolactinemia and the infertility that frequently accompanies it respond well to treatment with dopamine agonists, which inhibit pituitary prolactin release and thereby restore normal reproductive function. In addition, dopamine agonists usually facilitate the return of regular ovulatory menstrual cyclicity. Bromocriptine and cabergoline, the two dopamine agonists most commonly used for first-line treatment of hyperprolactinemia, have demonstrated efficacy even in the presence of pituitary adenomas. Cabergoline, with its improved tolerability, or other dopamine agonist alternatives may be used in patients who are intolerant of or resistant to bromocriptine. In amenorrheic, hyperprolactinemic women who desire to become pregnant, bromocriptine should be prescribed. However, women who are taking a long-acting dopamine agonist should discontinue the medication 1 month before trying to conceive.
AB - Hyperprolactinemia significantly impairs the normal functioning of the reproductive system in women by its detrimental effects on gonadotropin secretion, ovarian follicular development, oocyte release, and corpus luteum function. Fortunately, hyperprolactinemia and the infertility that frequently accompanies it respond well to treatment with dopamine agonists, which inhibit pituitary prolactin release and thereby restore normal reproductive function. In addition, dopamine agonists usually facilitate the return of regular ovulatory menstrual cyclicity. Bromocriptine and cabergoline, the two dopamine agonists most commonly used for first-line treatment of hyperprolactinemia, have demonstrated efficacy even in the presence of pituitary adenomas. Cabergoline, with its improved tolerability, or other dopamine agonist alternatives may be used in patients who are intolerant of or resistant to bromocriptine. In amenorrheic, hyperprolactinemic women who desire to become pregnant, bromocriptine should be prescribed. However, women who are taking a long-acting dopamine agonist should discontinue the medication 1 month before trying to conceive.
UR - http://www.scopus.com/inward/record.url?scp=0038826132&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038826132&partnerID=8YFLogxK
U2 - 10.1097/00003081-200306000-00013
DO - 10.1097/00003081-200306000-00013
M3 - Review article
C2 - 12808385
AN - SCOPUS:0038826132
SN - 0009-9201
VL - 46
SP - 349
EP - 362
JO - Clinical Obstetrics and Gynecology
JF - Clinical Obstetrics and Gynecology
IS - 2
ER -